Articles tagged with Cancer Cells
Scientists at Dana-Farber Cancer Institute have identified a new class of genes, dubbed CYCLOPS, that may serve as an Achilles' heel for many forms of cancer. These genes, which are essential to all cells but have been disrupted in cancer progression, can be targeted with drug molecules to block cancer cell proliferation.
Researchers propose targeting cancer cell communication to inspire new therapeutic approaches and potentially reactivate dormant cells. Cancer cells exhibit social behaviors like bacteria, including cooperation, task distribution, and immune evasion.
Researchers uncover chromosomal translocations that cause cancer, potentially leading to targeted therapies and personalized treatment. The study's findings may enable doctors to offer more accurate prognoses and inform treatment decisions.
Scientists have identified genetic alterations underlying a high-risk subtype of acute lymphoblastic leukemia (ALL) that can be effectively targeted with existing leukemia therapies. The study suggests patients with Ph-like ALL may benefit from the addition of imatinib and dasatinib to current chemotherapy regimens.
Researchers at Queen's University Belfast have discovered a new protein that plays a crucial role in regulating the spread of cancer cells. By targeting this protein, new therapies may be developed to prevent cancer from spreading.
Scientists are exploring ways to target cancer cells by attacking defective genes before protein production, leveraging micro RNAs (miRNAs) and their interactions with messenger RNAs. miR-7 and miR-128 affected pathways related to cell adhesion, EMT, and cellular replication in ovarian cancer cells.
Researchers have identified a new direction for cancer therapy by discovering a mutant form of the Chk1 gene that permanently stops cancer cell proliferation and causes cell death. This finding has the potential to reduce toxicity in cancer treatment, allowing physicians time to fix genetic errors.
A new study published in the FASEB Journal reveals that a molecule called 'flightless' significantly helps control cell movement through tissues. By increasing the stickiness of cells to underlying tissue, flightless slows their movement and may prevent cancer from spreading from one tissue to another.
A new biomarker, pyridoxal kinase (PDXK), has been identified as a predictor of response to chemotherapy in NSCLC patients. PDXK expression levels are associated with survival rates and treatment outcomes.
Researchers at Michigan Medicine have developed a safer method for steadying abnormal heart rhythms, using photodynamic therapy to target specific cells causing the arrhythmia. This cell-specific approach aims to decrease unwanted cell injury and inflammation, paving the way for more effective therapies.
Researchers found that paxillin regulates cell growth even in hormone therapy-resistant tumors, providing a new treatment target for advanced prostate cancer. The discovery could potentially lead to the development of targeted therapies that selectively attack cancer cells while leaving healthy cells intact.
Researchers at Arizona State University's Biodesign Institute developed the Cellarium, a live cell array technology that enables unprecedented insights into individual cell behavior. The system allows for dynamic measurements of live single cells, providing valuable clues to health and disease.
Researchers suggest using multicellular tumor spheroid (MCTS) models to improve cancer drug discovery, as they more accurately mimic human tumors. MCTS models can help identify specific genetic mutations targeted by drugs and interact with the surrounding environment.
Researchers at Moffitt Cancer Center found that inhibiting signal transducer and activator of transcription 3 (STAT3) can harness the immune system to eradicate residual malignant cells in drug-resistant mantle cell lymphoma. This strategy could provide a new approach for patients with therapy-resistant MCL.
Scientists at the Salk Institute have developed a protocol to convert cord blood cells into neuron-like cells, which may represent a new therapeutic option for neurological conditions. The method uses a single protein, Sox2, and demonstrates the conversion of cord blood cells into functional neurons.
A UCSF study reveals that a rare type of liver cancer may develop when one type of liver cell morphs into a totally different type, triggering tumors in mice. The discovery suggests that drugs targeting specific genes may provide a way to treat the deadly cancer.
Research established RNA Polymerase I (Pol I) activity as essential for cancer cell survival, and its inhibition with CX-5461 selectively activates p53 to kill tumors. The drug was shown to be 300 times more potent than non-genotoxic p53 activators.
A lipid, ceramide, helps cells find their way by keeping their antennae up, enabling direction and signal response. This function is crucial for maintaining proper cell locations, such as brain cells staying in the correct region.
A new strategy for treating aggressive skin cancer involves inducing cell differentiation to prevent tumor growth. Researchers identified a molecular mechanism that promotes the disappearance and inhibition of skin squamous cell carcinoma development.
Researchers have found that blocking a fundamental process deep within cancer cells can selectively kill them and spare normal cells. This discovery reveals that accelerated reading of ribosomal genes is responsible for causing abnormal nucleoli and is necessary for the survival of cancer cells.
Researchers at Ohio State University found that the loss of microRNA-125b (miR-125b) shuts down normal cell metabolism and enables cancer cells to proliferate. The study reveals a new mechanism by which chronic lymphocytic leukemia (CLL) develops, providing potential targets for new drugs.
Researchers at WashU Medicine discovered that ACA11, a non-coding RNA, helps protect cancer cells from damage and makes them resistant to chemotherapy. This finding may lead to new cancer therapeutics and help guide research into better treatments for patients with multiple myeloma.
Researchers discovered that combining EGFR inhibitors with Wnt pathway inhibition can improve the durability of lung cancer remission. The Wnt pathway allows lung cancer cells to escape from EGFR-targeted therapy, but disrupting this pathway could lengthen the usefulness of existing treatments.
Researchers at UCLA found that glucose starvation activates a metabolic and signaling amplification loop that leads to cancer cell death. The discovery reveals the power of systems biology in uncovering relationships between metabolism and signaling.
Weill Cornell researchers devise innovative boxer-like strategy to deliver one-two punch to multiple myeloma by weakening defenses and then killing cancer cells. The approach, using two anti-cancer drugs, shows potential for treating other tumor types.
Researchers at Notre Dame have engineered nanoparticles that can target cancer cells in bone marrow, reducing the development of drug resistance and allowing for more effective treatment. The particles also reduce toxic side effects on healthy organs, promising a new approach to multiple myeloma therapy.
A study published in the Journal of Thoracic Oncology found that stereotactic ablative radiotherapy is an effective treatment option for elderly patients with stage I non-small cell lung cancer. The treatment did not negatively impact health-related quality of life, and functional and symptom outcomes remained stable after two years.
A new study at University of Illinois Chicago found that the enzyme AMP-activated protein kinase (AMPK) helps cancer cells survive during initial tumor formation and when they spread to other organs. AMPK promotes cell survival by regulating NADPH, a molecule that reduces harmful reactive-oxygen species.
A team at NIST has developed a method to calibrate and optimize color-based imaging techniques for medical applications. This enhancement enables surgeons to detect specific cell types with improved accuracy. The NIST effort is part of a larger initiative to evaluate and validate optical medical imaging devices.
A population of cells in the squamo-columnar junction of the cervix have been found to be responsible for most HPV-associated cervical cancers. These cells can become cancerous when infected with HPV, while other cells in the cervix appear to be resistant to infection.
Researchers at the University of Kentucky have developed two new ruthenium complexes that are up to 200 times more toxic and three times more potent than cisplatin against tumor cells. These complexes become activated when exposed to light, reducing their impact on healthy cells.
Researchers found that mitochondrial DNA mutations are lower in colon cancer cells than normal cells, contradicting previous beliefs. This discovery suggests that increasing mitochondrial DNA damage may lead to cancer cell death with minimal side effects.
A phase II clinical study shows that vismodegib can dramatically shrink basal cell skin cancers and prevent new ones in patients with basal cell nevus syndrome, a rare genetic condition. The treatment offers an alternative to surgical removal, but side effects remain a consideration.
Researchers have identified a prototype compound that can directly activate the BAX protein, leading to apoptosis in cancer cells. This new paradigm for designing cancer drugs may lead to new therapeutic strategies.
Studies show that ligand cells produce pulling force to pull on Notch, activating cellular responses. The findings provide compelling evidence for the role of mechanical force in Notch signaling, potentially leading to new therapeutic targets for diseases related to Notch signaling.
Researchers at Penn State have developed a biochip-based device that can rapidly screen cells for leukemia or HIV. The device uses microfluidic drifting technology to focus particles or cells in a single stream, eliminating the need for bulky lenses and mirrors, and potentially reducing costs to $1,000 from current prices of $100,000.
Researchers have found that cancer cells may require simpler genetic mutations than previously thought to grow and proliferate. The most common hemizygous deletions in cancer involve tumor suppressing genes called STOP genes, which are haploinsufficient, meaning they depend on two copies to function normally.
Researchers developed a stapled BIM BH3 peptide that competitively binds to anti-apoptotic proteins, leading to enhanced apoptosis in cancer cells. The compound suppresses tumor growth in mice and works synergistically with other pharmaceutical agents.
Scientists develop a technique to measure internal cell temperatures without altering cellular metabolism, opening doors for studying metastasis and differentiating healthy from cancerous cells. The 'fluorescence polarisation anisotropy' method uses green fluorescent proteins to provide non-invasive temperature readings.
Researchers at Stanford University have developed a method to repeatedly encode, store and erase digital data within the DNA of living cells. This breakthrough enables the creation of a binary digit equivalent to a 'bit' in data parlance.
A new study describes a compound that selectively kills cancer cells by restoring the structure and function of mutant p53. This finding supports the development of rationally targeted cancer therapies and has potential for treating 30,000 patients annually in the US.
A Mayo Clinic study has found that exhaustion affects immune cells fighting cancer, rendering them less effective. The research suggests a new approach to lymphoma and other cancers by dampening cell-signaling molecules like IL-12.
Two UC Davis faculty members, Frederic Chedin and Noriko Satake, received Individual Biomedical Research Awards to explore novel approaches to understanding autoimmune diseases. Paula Goines, a postdoctoral researcher, will also receive funding for her work on autism research using nerve cells grown from adult stem cells.
The University of California, Santa Cruz, has established the Cancer Genomics Hub to manage and analyze large-scale cancer genomic data. This hub will support research programs like The Cancer Genome Atlas and enable personalized cancer care by connecting specific genomic changes with clinical outcomes.
Researchers have made a groundbreaking observation of cellular architecture using high-powered microscopes, revealing the structure of microtubules during gamete formation. The findings could impact the treatment of diseases caused by misregulation of microtubule structures, including Down syndrome and cancer.
Researchers have created a new instrument that rapidly analyzes the physical properties of cells to identify cancer and other cell states. The deformability cytometer measures cells' responses to fluid flow, providing valuable information about cell health.
Researchers have identified a second form of the MCL1 protein, which works in a different location and performs a different function. The newly discovered version is shorter and located inside mitochondria, where it promotes mitochondrial energy production and may aid in cancer treatment.
Researchers have found that adding boron-nitride nanotubes to cancer cells can increase the effectiveness of a minimally invasive treatment for soft tissue tumors. The treatment, known as Irreversible Electroporation, has been shown to kill twice as many cancer cells when BNNTs are present on the cell surface.
Researchers at Simon Fraser University found that cholesterol-binding proteins called ORPs can control cell growth, potentially slowing down cancer cells. Genetic changes blocked the ability of these proteins to bind cholesterol, but altered ORPs actually stimulated cell growth by activating regulator proteins.
Researchers at Huntsman Cancer Institute have discovered that normal epithelium tissue ejects living cells to maintain a steady population and ease overcrowding. This mechanism is crucial in preventing cancer, as it allows cells to turnover and prevents cell pile-ups, which are common in cancerous tissues.
Researchers create iPhage particles that penetrate cells using penetratin, targeting specific organelles like mitochondria and ribosomes. They discover a peptide ligand that disrupts ribosomal function, killing cancer cells and reducing cell survival in malignant and non-malignant cells.
Researchers develop new methods for injecting drugs and genetic payloads directly into cancer cells using plasmonic nanobubbles. Delivering chemotherapy with nanobubbles increases efficacy and reduces dosage, targeting single-cell level cancer treatment.
Researchers identified a novel anti-leukemia compound, Lenaldekar, that demonstrates effectiveness in eliminating immature zebrafish T-cells and targeting human T-ALL cell lines. The compound showed promise in treating cells from patients with other leukemias, including those resistant to current therapies.
Researchers discovered that the Nrf2 protein plays a crucial role in protecting cells from oxidative stress, which is often exploited by cancer cells to become resistant to treatment. By selectively inhibiting Nrf2, cancer cells may become more susceptible to chemotherapy and radiation therapy.
Researchers found EPR to be 30-46% better at identifying nonmelanoma skin cancer cases compared to claims data. The study suggests using EPR as an alternative for effectively tracking these cases, potentially improving disease burden estimates.
Researchers propose that non-genetic resistance can occur before genetic mutations, changing the approach to designing combination therapies. This new perspective aims to improve outcomes by understanding how cancers evolve and adapt to extreme challenges.
A new drug developed by Northwestern Medicine scientists has prevented human prostate cancer cells from spreading to other tissues. The drug inhibits movement of the cells and prevents metastasis without causing harm to normal cells or tissues.
Scientists have identified PRC2, a chromatin regulator, as a promising therapeutic target in acute myeloid leukemia. Blocking PRC2 halts uncontrolled proliferation and reactivates anti-tumor pathways, offering a potential new treatment option.
Scientists will investigate the role of Myc oncoproteins and a specific mRNA-binding protein, TTP, in controlling tumor growth. The study aims to define mechanisms that could lead to the development of new anti-cancer drugs.
New cell printing technology enables precise pattern formation of human cells, paving the way for advancement in tissue engineering and regeneration. Researchers demonstrated the use of acoustic droplet ejection followed by aqueous two-phase exclusion patterning to control cell placement.